News|Articles|January 28, 2026

3 insights from the third set of drugs for Medicare price negotiations

CMS announced 15 drugs for Medicare price negotiations under the IRA, representing $27 billion in spending and treating conditions such as diabetes, cancer, and autoimmune conditions. Here are three insights on the list from industry experts.

This morning, CMS released the names of the third set of drugs to be negotiated under the Inflation Reduction Act (IRA). The new maximum fair price (MFP) for these 15 products will be announced in November 2026, with implementation in January 2028.